Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report

dc.contributor.authorNathoo, Suninaen
dc.contributor.authorHood, William A.en
dc.contributor.authorKeihanian, Saraen
dc.contributor.authorCollinsworth, Amy L.en
dc.contributor.authorGlover, Sarah C.en
dc.date.accessioned2016-09-23T16:05:52Zen
dc.date.available2016-09-23T16:05:52Zen
dc.date.issued2016-09-23en
dc.date.updated2016-09-23T16:05:53Zen
dc.description.abstractBackground Esophageal Crohn’s disease is reported as a rare manifestation, although its prevalence may be underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn’s disease according to phase 2 trials. We report the first case of esophageal Crohn’s disease successfully treated with tofacitinib in a patient with worsening symptoms despite maintenance therapy with a tumor necrosis factor-α inhibitor. Case presentation A 67-year-old Caucasian woman presented with new dysphagia and had findings of esophageal Crohn’s disease on endoscopy. The dosage of her current biologic therapy—adalimumab—was increased in frequency, without improvement. Our patient was started on tofacitinib and demonstrated an improvement in symptoms, with a repeat endoscopy showing resolution of the previous lesions. Conclusion Esophageal Crohn’s disease is likely underdiagnosed but is an important consideration in a patient with new symptoms of dysphagia and known Crohn’s disease. Tofacitinib, while a novel agent, could have a role in the treatment of esophageal Crohn’s disease that does not improve with intensification of the current biologic therapy. It provides a different mechanism in patients who become refractory to maintenance therapy.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationJournal of Medical Case Reports. 2016 Sep 23;10(1):264en
dc.identifier.doihttps://doi.org/10.1186/s13256-016-1036-yen
dc.identifier.urihttp://hdl.handle.net/10919/73032en
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.holderThe Author(s)en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleTofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case reporten
dc.title.serialJournal of Medical Case Reportsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
13256_2016_Article_1036.pdf
Size:
3.18 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Item-specific license agreed upon to submission
Description: